Qiuyan Xu1, Hongyan Wang2, Yang Li2, Jinzhi Wang3, Yerui Lai2, Lin Gao4, Lu Lei4, Gangyi Yang2, Xin Liao4, Xia Fang2, Hua Liu5, Ling Li1. 1. Key Laboratory of Diagnostic Medicine (Ministry of Education) and Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, Chongqing, China. 2. Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. 3. Chongqing Key Lab of Child Infection and Immunity Children's Hospital of Chongqing Medical University, Chongqing, China. 4. Department of Endocrinology, the Affiliated Hospital, Zunyi Medical College, Chongqing, China. 5. Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA.
Abstract
BACKGROUND: Secreted frizzled-related protein-5 (Sfrp5) is a novel adipokine, and it has been found to link insulin resistance with diabetes. Animal studies have revealed the role of Sfrp5 in regulating lipid and glucose metabolism. The objective of this study was to investigate the relationship between Sfrp5 and the metabolic syndrome (MetS) in a cross-sectional study. METHODS: We conducted a series of cross-sectional studies of Chinese population including 194 control participants and 90 MetS patients. Circulating Sfrp5 concentrations were determined by ELISA. The relationships between circulating Sfrp5 levels and MetS components were assessed. RESULTS: Circulating Sfrp5 was significantly lower in newly examined MetS patients than in control participants (49.1 ± 17.2 vs 61.6 ± 23.2 μg/L, P < .01). Circulating Sfrp5 correlated negatively with markers of adiposity (waist-to-hip ratio, body mass index, and free fatty acids, P < .001 or P < .05). Furthermore, Sfrp5 levels correlated with fasting insulin, 2 h-ins, fasting blood glucose, 2 h post-glucose load blood glucose, HbA1c , and homeostasis model assessment of insulin resistance. In addition, circulating Sfrp5 levels were closely associated with blood pressure, high-density lipoprotein cholesterol, triglycerides, and atherosclerotic index. Circulating concentrations of Sfrp5 decreased progressively with continued increases in the numbers of MetS components. The analysis of receiver operating characteristic curves revealed that the best cutoff value for circulating Sfrp5 to predict MetS was 46.8 μg/L (sensitivity 70.1 %, specificity 47.8 %, and AUC 0.66). CONCLUSIONS: We conclude that Sfrp5 may be an adipokine that is associated with the pathogenesis of MetS in humans.
BACKGROUND:Secreted frizzled-related protein-5 (Sfrp5) is a novel adipokine, and it has been found to link insulin resistance with diabetes. Animal studies have revealed the role of Sfrp5 in regulating lipid and glucose metabolism. The objective of this study was to investigate the relationship between Sfrp5 and the metabolic syndrome (MetS) in a cross-sectional study. METHODS: We conducted a series of cross-sectional studies of Chinese population including 194 control participants and 90 MetS patients. Circulating Sfrp5 concentrations were determined by ELISA. The relationships between circulating Sfrp5 levels and MetS components were assessed. RESULTS: Circulating Sfrp5 was significantly lower in newly examined MetS patients than in control participants (49.1 ± 17.2 vs 61.6 ± 23.2 μg/L, P < .01). Circulating Sfrp5 correlated negatively with markers of adiposity (waist-to-hip ratio, body mass index, and free fatty acids, P < .001 or P < .05). Furthermore, Sfrp5 levels correlated with fasting insulin, 2 h-ins, fasting blood glucose, 2 h post-glucose load blood glucose, HbA1c , and homeostasis model assessment of insulin resistance. In addition, circulating Sfrp5 levels were closely associated with blood pressure, high-density lipoprotein cholesterol, triglycerides, and atherosclerotic index. Circulating concentrations of Sfrp5 decreased progressively with continued increases in the numbers of MetS components. The analysis of receiver operating characteristic curves revealed that the best cutoff value for circulating Sfrp5 to predict MetS was 46.8 μg/L (sensitivity 70.1 %, specificity 47.8 %, and AUC 0.66). CONCLUSIONS: We conclude that Sfrp5 may be an adipokine that is associated with the pathogenesis of MetS in humans.
Authors: Maren Carstensen-Kirberg; Julia M Kannenberg; Cornelia Huth; Christa Meisinger; Wolfgang Koenig; Margit Heier; Annette Peters; Wolfgang Rathmann; Michael Roden; Christian Herder; Barbara Thorand Journal: Cardiovasc Diabetol Date: 2017-08-29 Impact factor: 9.951